Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of active duodenal ulcer,Prophylaxis of recurrent duodenal ulcer,Treatment of active benign gastric ulcer,Prophylaxis of gastric ulcer in patients at risk,Treatment of gastroesophageal reflux disease (GERD),Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Prophylaxis of stress ulcer in critically ill patients,Prevention of aspiration pneumonitis during anesthesia (off-label),Treatment of urticaria (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: approximately 2 hours in healthy adults; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Hepatic metabolism via N-oxidation, S-oxidation, and demethylation; major pathway is N-oxidation. CYP450 involvement is minimal; primarily metabolized by flavin-containing monooxygenase (FMO3).
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minor (approximately 10-15% as metabolites).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
13-25% bound to plasma proteins (primarily albumin).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
1.0-2.0 L/kg; large Vd indicates extensive tissue distribution (e.g., muscle, kidney, liver).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: 60-70% (due to first-pass metabolism); intravenous: 100%.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
For Cr Cl 30-50 m L/min: 300 mg IV every 8 hours. For Cr Cl 15-29 m L/min: 300 mg IV every 12 hours. For Cr Cl <15 m L/min: 300 mg IV every 24 hours.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment for Child-Pugh; use caution and reduce dose in severe hepatic impairment based on clinical response, as clearance may be decreased.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Neonates: 5-10 mg/kg IV every 8-12 hours. Infants and children: 5-10 mg/kg IV every 6-8 hours, not to exceed 300 mg per dose. Adolescents: 300 mg IV every 6-8 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Reduce dose based on renal function; start at lower end of dosing range (e.g., 300 mg IV every 12 hours if Cr Cl 30-50 m L/min) and titrate to response. Monitor for CNS side effects.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause confusion, hallucinations, or delirium (especially in elderly, renally impaired, or critically ill patients),May cause hepatotoxicity (elevated liver enzymes, hepatitis),May cause bone marrow suppression (neutropenia, agranulocytosis; rare),May cause bradycardia or cardiac arrhythmias with rapid IV administration,May inhibit cytochrome P450 (CYP1A2, CYP2C19, CYP2D6, CYP3A4) leading to increased levels of coadministered drugs (e.g., warfarin, theophylline, phenytoin),May cause gynecomastia or impotence with prolonged high doses,Use with caution in patients with renal impairment (dose adjustment required)
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to cimetidine or any component of the formulation,Use in patients with porphyria (may precipitate acute attacks),May interfere with vitamin B12 absorption (long-term use associated with deficiency)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Cimetidine may increase absorption of alcohol, leading to higher blood alcohol levels. Avoid alcohol. High-fat meals may slightly decrease absorption, but not clinically significant. No specific food restrictions.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of fetal harm, but cimetidine has been associated with transient neonatal hepatic impairment and antiandrogenic effects in animal studies (dose-dependent). Use only if clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Cimetidine is excreted into human breast milk (M/P ratio approximately 0.7). Peak milk levels occur 1-2 hours after dose. Milk levels are ~10-20% of maternal serum levels. Dose equivalent to infant is about 6-10% of maternal weight-adjusted dose. Caution: potential for anticholinergic effects in the infant. Monitor infant for drowsiness, bradycardia, or hypotonia. Alternative agents (e.g., ranitidine) are preferred.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No pharmacokinetic-specific dose adjustments are standard for cimetidine in pregnancy. However, due to increased renal clearance in pregnancy and possible altered hepatic metabolism, consider dosing at the lower end of the effective range (e.g., 300 mg IV q6-8h) and monitor therapeutic response. For continuous infusion, consider dose reduction in renal impairment.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Cimetidine is a potent inhibitor of CYP1A2, CYP2C19, CYP2D6, and CYP3A4, leading to increased serum levels of many drugs including warfarin, theophylline, phenytoin, and lidocaine. In elderly or renally impaired patients, reduce dose to prevent CNS side effects like confusion or hallucinations. Rapid IV administration can cause hypotension or cardiac arrhythmias; infuse over at least 30 minutes. Monitor for elevated serum creatinine initially due to interference with tubular secretion of creatinine.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Do not smoke while taking this medication, as smoking can decrease its effectiveness.,Avoid alcohol consumption, which can worsen stomach irritation.,Inform your doctor about all medications you take, as cimetidine can interact with many drugs.,Report any confusion, dizziness, or unusual bleeding/bruising immediately.,Take exactly as prescribed; do not increase the dose without consulting your healthcare provider.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of f. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.